Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts. Wong, S. K., Whisenant, J. G., Bestvina, C. M., Berry, L. D., Owonikoko, T. K., Sanborn, R. E., Lammers, P., El Osta, B., Ramalingam, S. S., Carlisle, J. W., Steuer, C., Borghaei, H., Selvaggi, G., Shyr, Y., Wakelee, H. A., Horn, L., Beckermann, K. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.2578
View details for Web of Science ID 000708120601099